Exhibit 99

     TRANSGENOMIC REGAINS COMPLIANCE WITH NASDAQ CONTINUED LISTING STANDARD

    OMAHA, Neb., Sept. 19 /PRNewswire-FirstCall/ -- Transgenomic Inc.
(Nasdaq: TBIO) announced today that it received notification from The NASDAQ
Stock Market that the company has regained compliance with the $1.00 minimum
bid price requirement for continued listing on NASDAQ's National Market.

    Collin D'Silva, CEO, believes that recent realigning of the business
resulted in improved performance that was essential to regaining compliance with
the NASDAQ continued listing standard. "We've placed a renewed focus on our
BioSystems business, which in our view offers the best mix of current and future
opportunities going forward," said D'Silva. "This strategic change is reflected
in the improved financial results in the first two quarters of 2005 for
Transgenomic, including our historic best quarterly operating performance in the
second quarter." D'Silva concluded, "With accelerated growth in revenue in the
second half of the year, we should be in position to further improve our
financial performance in the last two quarters of this year and going forward."

    Last March NASDAQ notified the company that its stock had not maintained the
minimum closing bid price of $1.00 as required by Marketplace Rule 4450(a)(5)
and that its common stock was subject to delisting from the NASDAQ National
Market. NASDAQ gave the company until September 27 to regain compliance with the
minimum bid price listing standard. In its notification that the company has
regained compliance, NASDAQ indicated that the company's stock demonstrated an
ability to maintain long-term compliance with this listing standard by closing
at or above $1.00 for 10 consecutive business days. The company's security is no
longer subject to the previously announced notification of delisting.

    About Transgenomic

    Transgenomic provides versatile and innovative research tools and related
consumable products. Transgenomic's BioSystems segment offers its WAVE Systems
and associated consumables. These systems are specifically designed for use in
genetic variation detection and single- and double-strand DNA/RNA analysis and
purification. These systems have broad applicability to genetic research and
molecular diagnostics. To date there have been approximately one thousand
systems installed in over 30 countries around the world. In addition, the
BioSystems segment offers WAVE-based biomarker discovery and validation services
in support of translational research, pre-clinical and clinical studies. Through
its Nucleic Acids business segment, Transgenomic provides specialty chemicals,
including advanced nucleic acid building blocks and associated reagents used in
the manufacture of synthetic oligonucleotides. For more information about the
innovative genomics research tools developed and marketed by Transgenomic,
please visit the company's Web site at www.transgenomic.com.

    Forward-Looking Statement

    Certain statements in this press release constitute "forward-looking
statements" of Transgenomic within the meaning of the Private Securities
Litigation Reform Act of 1995, which involve known and unknown risks,
uncertainties and other factors that may cause our actual results to be
materially different from any future results, performance or achievements
expressed or implied by such statements. Forward-looking statements include, but
are not limited to, those with respect to management's current views and
estimates of future economic circumstances, industry conditions, company
performance and financial results, including the ability to achieve improved
financial performance and neutral to positive operating cash flow by year end.
The known risks, uncertainties and other factors affecting these forward-looking
statements are described from time to time in Transgenomic's reports to the
Securities and Exchange Commission. Any change in such factors, risks and
uncertainties may cause the actual results, events and performance to differ
materially from those referred to in such statements. Accordingly, the company
claims the protection of the safe harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995 with respect
to all statements contained in this press release. All information in this press
release is as of the date of the release and Transgenomic does not undertake any
duty to update this information, including any forward-looking statements,
unless required by law.

SOURCE  Transgenomic Inc.
    -0-                             09/19/2005
    /CONTACT:  Investors, Paul G. Henning of Cameron Associates,
+1-212-554-5462, phenning@cameronassoc.com, for Transgenomic Inc.; or
Robert J. Pogulis, Ph.D. of Transgenomic Inc., +1-845-782-9617,
rpogulis@transgenomic.com/
    /Web site:  http://www.transgenomic.com /